Contineum Therapeutics, Class Stock Alpha and Beta Analysis
| CTNM Stock | 12.41 0.27 2.13% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Contineum Therapeutics, Class. It also helps investors analyze the systematic and unsystematic risks associated with investing in Contineum Therapeutics, over a specified time horizon. Remember, high Contineum Therapeutics,'s alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Contineum Therapeutics,'s market risk premium analysis include:
Beta 0.51 | Alpha 0.25 | Risk 4.02 | Sharpe Ratio 0.0391 | Expected Return 0.16 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Contineum | Build AI portfolio with Contineum Stock |
Contineum Therapeutics, Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Contineum Therapeutics, market risk premium is the additional return an investor will receive from holding Contineum Therapeutics, long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Contineum Therapeutics,. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Contineum Therapeutics,'s performance over market.| α | 0.25 | β | 0.51 |
Contineum Therapeutics, expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Contineum Therapeutics,'s Buy-and-hold return. Our buy-and-hold chart shows how Contineum Therapeutics, performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Contineum Therapeutics, Market Price Analysis
Market price analysis indicators help investors to evaluate how Contineum Therapeutics, stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Contineum Therapeutics, shares will generate the highest return on investment. By understating and applying Contineum Therapeutics, stock market price indicators, traders can identify Contineum Therapeutics, position entry and exit signals to maximize returns.
Contineum Therapeutics, Return and Market Media
The median price of Contineum Therapeutics, for the period between Sun, Sep 28, 2025 and Sat, Dec 27, 2025 is 11.12 with a coefficient of variation of 5.68. The daily time series for the period is distributed with a sample standard deviation of 0.65, arithmetic mean of 11.38, and mean deviation of 0.54. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | How Contineum Therapeutics Inc. stock compares to growth peers - July 2025 Technicals Fast Exit Strategy with Risk Control - newser.com | 10/27/2025 |
2 | JonesTrading Maintains Contineum Therapeutics With Buy Rating, Raises Target Price to 25 - | 11/06/2025 |
3 | Morgan Stanley Raises Price Target on Contineum Therapeutics to 23 From 21, Keeps Overweight Rating - MarketScreener | 11/17/2025 |
4 | Contineum Therapeutics Multiple Sclerosis Trial Disappoints, But Analyst Sees Other Assets Driving Value | 11/21/2025 |
5 | CTNM - Contineum Therapeutics Latest Stock News Market Updates - Stock Titan | 11/25/2025 |
6 | Contineum Therapeutics Announces Proposed 75.0 Million Public Offering | 12/11/2025 |
7 | Wall Street Zen Downgrades Contineum Therapeutics to Sell | 12/15/2025 |
8 | Contineum Therapeutics Upgraded at Wall Street Zen | 12/24/2025 |
About Contineum Therapeutics, Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Contineum or other stocks. Alpha measures the amount that position in Contineum Therapeutics, has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | Interest Debt Per Share | 0.32 | 0.31 | Revenue Per Share | 1.78 | 1.58 |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Contineum Therapeutics, in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Contineum Therapeutics,'s short interest history, or implied volatility extrapolated from Contineum Therapeutics, options trading.
Build Portfolio with Contineum Therapeutics,
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Contineum Therapeutics, Backtesting, Contineum Therapeutics, Valuation, Contineum Therapeutics, Correlation, Contineum Therapeutics, Hype Analysis, Contineum Therapeutics, Volatility, Contineum Therapeutics, History and analyze Contineum Therapeutics, Performance. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Contineum Therapeutics, technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.